MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer

Not Applicable

Recruiting

• Conditions: Endometrial Cancer

• Registration Number: NCT06677112
• Lead Sponsor: Rachel Miller

Brief Summary

This study aims to estimate the recurrence-free survival rates in women with endometrial cancer treated with selective versus sentinel node surgical staging. This study will gather information to help determine the best way to evaluate lymph nodes during surgery for endometrial cancer.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-11-04
• Study First Submitted QC: 2024-11-04
• Study First Posted: 2024-11-06
• Study Start: 2025-03-17
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-28
• Last Update Posted: 2025-05-01
• Primary Completion: 2030-01
• Study Completion: 2030-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 625

Inclusion Criteria

• Surgical candidate for complete hysterectomy and bilateral salpingooophorectomy with pelvic and aortic lymphadenectomy
• Histologically or cytologically confirmed carcinoma of the endometrium confined to the uterine corpus
• No clinical evidence of extra-uterine disease on pre-operative evaluation. Preoperative evaluation to rule-out extra-uterine disease may include a CT scan, MRI or ultrasound. Note: preoperative imaging is not mandatory for study enrollment.
• Prior systemic chemotherapy is allowed so long as it was at least five years prior to study enrollment, and there is no evidence of disease after such therapy.

Neoadjuvant chemotherapy for this endometrial cancer is not allowed.

• Life expectancy (estimated survival) of at least 6 months.
• AST(SGOT)/ALT(SGPT) < 3.0X upper limit of normal
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

• GOG Performance Status greater than 2 (Appendix II)
• Uterine sarcoma
• Clinical evidence of disease that extends beyond the uterus, including the presence of suspicious aortic or inguinal nodes on imaging or clinical exam
• Previous vaginal, pelvic or abdominal irradiation
• Chemotherapy, hormone therapy or immunotherapy directed at the present disease
• Previous pelvic lymphadenectomy or retroperitoneal surgery
• Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen should be excluded
• Known allergy to iodine or indocyanine green (ICG) tracer, or allergic reactions to compounds of similar chemical or biologic composition
• Patients with uncontrolled intercurrent illness
• Patients with psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant or lactating women. Women of child-bearing potential will be excluded if they have a positive serum/urine pregnancy test

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Recurrence free survival	up to 5 years	Participants with no measurable disease from study entry until disease recurrence, death, or date of the last contact

Secondary Outcome Measures

Name	Time	Method
Concordance between selective surgical staging and final pathology Incidence	5 years	Percentage of participants for whom selective surgical staging and final pathology match
Progression-free survival	up to 5 years	period from study entry until disease progression, death, or date of the last contact
Disease-specific Survival	up to 5 years	period from study entry until death from the disease (endometrial cancer)
Overall patient survival rate	5 years	period from study entry until death from any cause

Trial Locations

Locations (1)

University of Kentucky; 🇺🇸 Lexington, Kentucky, United States